GRI Stock Forecast & Price Target

GRI Bio is viewed favorably because GRI-0621’s Phase 2a IPF readout met primary, secondary, and exploratory endpoints, while also showing a clean safety profile, FVC gains versus placebo, and biomarker shifts consistent with fibrosis resolution and alveolar repair. The 35-patient biomarker package and 12-week clinical data suggest a differentiated RARβ/γ mechanism that could both halt and potentially reverse disease biology, which stands out versus approved antifibrotics that only slow progression. The balance sheet adds support, with $11 million in cash, no debt, and cash runway into late-2027, while the company’s ~billion dollars market potential and advancing FDA discussions strengthen the long-term upside case.

GRI Bio is a clinical-stage biotech with no revenue, and its fiscal Q1 2026 net loss of $2.0 million underscored continued cash burn while management provided no guidance to offset funding concerns. Its value rests heavily on GRI-0621, which is only assigned a 20% probability of success and is still dependent on the U.S. IPF opportunity, leaving a narrow and highly speculative base. The pipeline remains early, with GRI-0803 still preclinical, while failed trials, dilutive capital raises, regulatory setbacks, and delisting risk create a challenging fundamental setup for shareholders.